Management of patients with HBeAg-negative chronic hepatitis B.
Postgrad Med J
; 83(975): 32-9, 2007 Jan.
Article
in En
| MEDLINE
| ID: mdl-17267676
ABSTRACT
Chronic hepatitis B (CHB) is one of the leading causes of morbidity and mortality worldwide. Although various drugs are available for the treatment of CHB, emergence of the hepatitis B e antigen (HBeAg)-negative mutant variant, specifically in Asia, the Middle East and southern Europe, is creating a new challenge as this variant is less responsive to available treatments. HBeAg-negative CHB rapidly progresses to cirrhosis and its related complications. This review discusses the available literature on the approved and under-trial treatment options and their respective efficacies for HBeAg-negative CHB.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Hepatitis B, Chronic
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Postgrad Med J
Year:
2007
Document type:
Article
Affiliation country:
India